Chemoradiation then durvalumab (PACIFIC)
Checked 2026-09-09
Unresectable stage III NSCLC without progression after platinum-based chemoradiation
One cycle
every 28 days × 12 · about 48 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Durvalumab Monoclonal antibody (anti-PD-L1) | 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks | IV | D1 |
Cycles
12 months of durvalumab
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Start within 42 days of the last radiotherapy fraction; pneumonitis risk is additive with radiation.
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Trastuzumab deruxtecan 5.4 mg/kg
HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC
every 21 days
Pembrolizumab + pemetrexed + platinum
Metastatic non-squamous NSCLC without EGFR/ALK alteration, first line, any PD-L1
every 21 days × 4
Pembrolizumab + carboplatin + paclitaxel
Metastatic squamous NSCLC, first line
every 21 days × 4
Nivolumab + ipilimumab + 2 cycles of platinum doublet
Metastatic NSCLC without EGFR/ALK alteration, first line
every 21 days
Osimertinib
EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)
every 28 days
Cisplatin + vinorelbine (adjuvant)
Completely resected stage IB (4 cm or larger) to IIIA NSCLC
every 28 days × 4
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Cisplatin + pemetrexed
Unresectable pleural mesothelioma (with or without bevacizumab); non-squamous NSCLC
every 21 days × 6